The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Global Acute Coronary Syndrome (ACS) Market Research Report 2024
Synopsis
Acute coronary syndrome (ACS) is a syndrome (set of signs and symptoms) due to decreased blood flow in the coronary arteries such that part of the heart muscle is unable to function properly or dies. The most common symptom is chest pain, often radiating to the left shoulder or angle of the jaw, crushing, central and associated with nausea and sweating. Many people with acute coronary syndromes present with symptoms other than chest pain, particularly, women, older patients, and patients with diabetes mellitus.
The global Acute Coronary Syndrome (ACS) market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
Increase in geriatric population and rise in the incidence of cardiac disorders are the major factors that drive the market growth. However, stringent government regulations for the approval of drugs are expected to restrain the market growth. Improvement in healthcare facilities in emerging regions such as Asia-Pacific and LAMEA are expected to provide new growth opportunities for the market during the analysis period.
This report aims to provide a comprehensive presentation of the global market for Acute Coronary Syndrome (ACS), with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Acute Coronary Syndrome (ACS).
Report Scope
The Acute Coronary Syndrome (ACS) market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Acute Coronary Syndrome (ACS) market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Acute Coronary Syndrome (ACS) companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Dexa Medica
GlaxoSmithKline
Novartis
Pfizer
Sanofi
Serum Institute of India
Biogen
Eli Lilly and Company
Segment by Type
Monotherapy
Combination Therapy
Segment by Application
Hospitals
Ambulatory Surgical Center
Diagnostic Centers
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Acute Coronary Syndrome (ACS) companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Acute coronary syndrome (ACS) is a syndrome (set of signs and symptoms) due to decreased blood flow in the coronary arteries such that part of the heart muscle is unable to function properly or dies. The most common symptom is chest pain, often radiating to the left shoulder or angle of the jaw, crushing, central and associated with nausea and sweating. Many people with acute coronary syndromes present with symptoms other than chest pain, particularly, women, older patients, and patients with diabetes mellitus.
The global Acute Coronary Syndrome (ACS) market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
Increase in geriatric population and rise in the incidence of cardiac disorders are the major factors that drive the market growth. However, stringent government regulations for the approval of drugs are expected to restrain the market growth. Improvement in healthcare facilities in emerging regions such as Asia-Pacific and LAMEA are expected to provide new growth opportunities for the market during the analysis period.
This report aims to provide a comprehensive presentation of the global market for Acute Coronary Syndrome (ACS), with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Acute Coronary Syndrome (ACS).
Report Scope
The Acute Coronary Syndrome (ACS) market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Acute Coronary Syndrome (ACS) market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Acute Coronary Syndrome (ACS) companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Dexa Medica
GlaxoSmithKline
Novartis
Pfizer
Sanofi
Serum Institute of India
Biogen
Eli Lilly and Company
Segment by Type
Monotherapy
Combination Therapy
Segment by Application
Hospitals
Ambulatory Surgical Center
Diagnostic Centers
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Acute Coronary Syndrome (ACS) companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Index1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Acute Coronary Syndrome (ACS) Market Size Growth Rate by Type: 2019 VS 2023 VS 2030
1.2.2 Monotherapy
1.2.3 Combination Therapy
1.3 Market by Application
1.3.1 Global Acute Coronary Syndrome (ACS) Market Growth by Application: 2019 VS 2023 VS 2030
1.3.2 Hospitals
1.3.3 Ambulatory Surgical Center
1.3.4 Diagnostic Centers
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Acute Coronary Syndrome (ACS) Market Perspective (2019-2030)
2.2 Acute Coronary Syndrome (ACS) Growth Trends by Region
2.2.1 Global Acute Coronary Syndrome (ACS) Market Size by Region: 2019 VS 2023 VS 2030
2.2.2 Acute Coronary Syndrome (ACS) Historic Market Size by Region (2019-2024)
2.2.3 Acute Coronary Syndrome (ACS) Forecasted Market Size by Region (2025-2030)
2.3 Acute Coronary Syndrome (ACS) Market Dynamics
2.3.1 Acute Coronary Syndrome (ACS) Industry Trends
2.3.2 Acute Coronary Syndrome (ACS) Market Drivers
2.3.3 Acute Coronary Syndrome (ACS) Market Challenges
2.3.4 Acute Coronary Syndrome (ACS) Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Acute Coronary Syndrome (ACS) Players by Revenue
3.1.1 Global Top Acute Coronary Syndrome (ACS) Players by Revenue (2019-2024)
3.1.2 Global Acute Coronary Syndrome (ACS) Revenue Market Share by Players (2019-2024)
3.2 Global Acute Coronary Syndrome (ACS) Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Acute Coronary Syndrome (ACS) Revenue
3.4 Global Acute Coronary Syndrome (ACS) Market Concentration Ratio
3.4.1 Global Acute Coronary Syndrome (ACS) Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Acute Coronary Syndrome (ACS) Revenue in 2023
3.5 Acute Coronary Syndrome (ACS) Key Players Head office and Area Served
3.6 Key Players Acute Coronary Syndrome (ACS) Product Solution and Service
3.7 Date of Enter into Acute Coronary Syndrome (ACS) Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Acute Coronary Syndrome (ACS) Breakdown Data by Type
4.1 Global Acute Coronary Syndrome (ACS) Historic Market Size by Type (2019-2024)
4.2 Global Acute Coronary Syndrome (ACS) Forecasted Market Size by Type (2025-2030)
5 Acute Coronary Syndrome (ACS) Breakdown Data by Application
5.1 Global Acute Coronary Syndrome (ACS) Historic Market Size by Application (2019-2024)
5.2 Global Acute Coronary Syndrome (ACS) Forecasted Market Size by Application (2025-2030)
6 North America
6.1 North America Acute Coronary Syndrome (ACS) Market Size (2019-2030)
6.2 North America Acute Coronary Syndrome (ACS) Market Growth Rate by Country: 2019 VS 2023 VS 2030
6.3 North America Acute Coronary Syndrome (ACS) Market Size by Country (2019-2024)
6.4 North America Acute Coronary Syndrome (ACS) Market Size by Country (2025-2030)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Acute Coronary Syndrome (ACS) Market Size (2019-2030)
7.2 Europe Acute Coronary Syndrome (ACS) Market Growth Rate by Country: 2019 VS 2023 VS 2030
7.3 Europe Acute Coronary Syndrome (ACS) Market Size by Country (2019-2024)
7.4 Europe Acute Coronary Syndrome (ACS) Market Size by Country (2025-2030)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Acute Coronary Syndrome (ACS) Market Size (2019-2030)
8.2 Asia-Pacific Acute Coronary Syndrome (ACS) Market Growth Rate by Region: 2019 VS 2023 VS 2030
8.3 Asia-Pacific Acute Coronary Syndrome (ACS) Market Size by Region (2019-2024)
8.4 Asia-Pacific Acute Coronary Syndrome (ACS) Market Size by Region (2025-2030)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Acute Coronary Syndrome (ACS) Market Size (2019-2030)
9.2 Latin America Acute Coronary Syndrome (ACS) Market Growth Rate by Country: 2019 VS 2023 VS 2030
9.3 Latin America Acute Coronary Syndrome (ACS) Market Size by Country (2019-2024)
9.4 Latin America Acute Coronary Syndrome (ACS) Market Size by Country (2025-2030)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Acute Coronary Syndrome (ACS) Market Size (2019-2030)
10.2 Middle East & Africa Acute Coronary Syndrome (ACS) Market Growth Rate by Country: 2019 VS 2023 VS 2030
10.3 Middle East & Africa Acute Coronary Syndrome (ACS) Market Size by Country (2019-2024)
10.4 Middle East & Africa Acute Coronary Syndrome (ACS) Market Size by Country (2025-2030)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Dexa Medica
11.1.1 Dexa Medica Company Detail
11.1.2 Dexa Medica Business Overview
11.1.3 Dexa Medica Acute Coronary Syndrome (ACS) Introduction
11.1.4 Dexa Medica Revenue in Acute Coronary Syndrome (ACS) Business (2019-2024)
11.1.5 Dexa Medica Recent Development
11.2 GlaxoSmithKline
11.2.1 GlaxoSmithKline Company Detail
11.2.2 GlaxoSmithKline Business Overview
11.2.3 GlaxoSmithKline Acute Coronary Syndrome (ACS) Introduction
11.2.4 GlaxoSmithKline Revenue in Acute Coronary Syndrome (ACS) Business (2019-2024)
11.2.5 GlaxoSmithKline Recent Development
11.3 Novartis
11.3.1 Novartis Company Detail
11.3.2 Novartis Business Overview
11.3.3 Novartis Acute Coronary Syndrome (ACS) Introduction
11.3.4 Novartis Revenue in Acute Coronary Syndrome (ACS) Business (2019-2024)
11.3.5 Novartis Recent Development
11.4 Pfizer
11.4.1 Pfizer Company Detail
11.4.2 Pfizer Business Overview
11.4.3 Pfizer Acute Coronary Syndrome (ACS) Introduction
11.4.4 Pfizer Revenue in Acute Coronary Syndrome (ACS) Business (2019-2024)
11.4.5 Pfizer Recent Development
11.5 Sanofi
11.5.1 Sanofi Company Detail
11.5.2 Sanofi Business Overview
11.5.3 Sanofi Acute Coronary Syndrome (ACS) Introduction
11.5.4 Sanofi Revenue in Acute Coronary Syndrome (ACS) Business (2019-2024)
11.5.5 Sanofi Recent Development
11.6 Serum Institute of India
11.6.1 Serum Institute of India Company Detail
11.6.2 Serum Institute of India Business Overview
11.6.3 Serum Institute of India Acute Coronary Syndrome (ACS) Introduction
11.6.4 Serum Institute of India Revenue in Acute Coronary Syndrome (ACS) Business (2019-2024)
11.6.5 Serum Institute of India Recent Development
11.7 Biogen
11.7.1 Biogen Company Detail
11.7.2 Biogen Business Overview
11.7.3 Biogen Acute Coronary Syndrome (ACS) Introduction
11.7.4 Biogen Revenue in Acute Coronary Syndrome (ACS) Business (2019-2024)
11.7.5 Biogen Recent Development
11.8 Eli Lilly and Company
11.8.1 Eli Lilly and Company Company Detail
11.8.2 Eli Lilly and Company Business Overview
11.8.3 Eli Lilly and Company Acute Coronary Syndrome (ACS) Introduction
11.8.4 Eli Lilly and Company Revenue in Acute Coronary Syndrome (ACS) Business (2019-2024)
11.8.5 Eli Lilly and Company Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
